David G Koch1, J L Speiser1, V Durkalski1, R J Fontana2, T Davern3, B McGuire4, R T Stravitz5, A M Larson6, I Liou6, O Fix7, M L Schilsky8, T McCashland9, J E Hay10, N Murray11, O S Shaikh12, D Ganger13, A Zaman14, S B Han15, R T Chung16, R S Brown17, S Munoz18, K R Reddy18, L Rossaro19, R Satyanarayana20, A J Hanje21, J Olson22, R M Subramanian23, C Karvellas24, B Hameed25, A H Sherker26, W M Lee27, A Reuben1. 1. Medical University of South Carolina, Charleston, South Carolina, USA. 2. University of Michigan, Ann Arbor, Michigan, USA. 3. California Pacific Medical Center, San Francisco, California, USA. 4. University of Alabama, Birmingham, Alabama, USA. 5. Virginia Commonwealth University, Richmond, Virginia, USA. 6. University of Washington, Seattle, Washington, USA. 7. Swedish Medical Center Seattle, Seattle, Washington, USA. 8. Yale University, New Haven, Connecticut, USA. 9. University of Nebraska Medical Center, Omaha, Nebraska, USA. 10. Mayo Clinic, Rochester, Minnesota, USA. 11. Baylor University Medical Center, Dallas, Texas, USA. 12. University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 13. Northwestern University, Evanston, Illinois, USA. 14. Oregon Health Sciences Center, Portland, Oregon, USA. 15. University of California, Los Angeles, California, USA. 16. Massachusetts General Hospital, Boston, Massachusetts, USA. 17. Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA. 18. University of Pennsylvania, Philadelphia, Pennsylvania, USA. 19. University of California, Davis, California, USA. 20. Mayo Clinic, Jacksonville, Florida, USA. 21. The Ohio State University, Columbus, Ohio, USA. 22. University of Kansas Medical Center, Kansas City, Kansas, USA. 23. Emory University, Atlanta, Georgia, USA. 24. University of Alberta, Edmonton, Alberta, Canada. 25. University of California, San Francisco, California, USA. 26. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA. 27. University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Abstract
OBJECTIVES: Acute liver failure (ALF) is classically defined by coagulopathy and hepatic encephalopathy (HE); however, acute liver injury (ALI), i.e., severe acute hepatocyte necrosis without HE, has not been carefully defined nor studied. Our aim is to describe the clinical course of specifically defined ALI, including the risk and clinical predictors of poor outcomes, namely progression to ALF, the need for liver transplantation (LT) and death. METHODS: 386 subjects prospectively enrolled in the Acute Liver Failure Study Group registry between 1 September 2008 through 25 October 2013, met criteria for ALI: International Normalized Ratio (INR)≥2.0 and alanine aminotransferase (ALT)≥10 × elevated (irrespective of bilirubin level) for acetaminophen (N-acetyl-p-aminophenol, APAP) ALI, or INR≥2.0, ALT≥10x elevated, and bilirubin≥3.0 mg/dl for non-APAP ALI, both groups without any discernible HE. Subjects who progressed to poor outcomes (ALF, death, LT) were compared, by univariate analysis, with those who recovered. A model to predict poor outcome was developed using the random forest (RF) procedure. RESULTS: Progression to a poor outcome occurred in 90/386 (23%), primarily in non-APAP (71/179, 40%) vs. only 14/194 (7.2%) in APAP patients comprising 52% of all cases (13 cases did not have an etiology assigned; 5 of whom had a poor outcome). Of 82 variables entered into the RF procedure: etiology, bilirubin, INR, APAP level and duration of jaundice were the most predictive of progression to ALF, LT, or death. CONCLUSIONS: A majority of ALI cases are due to APAP, 93% of whom will improve rapidly and fully recover, while non-APAP patients have a far greater risk of poor outcome and should be targeted for early referral to a liver transplant center.
OBJECTIVES:Acute liver failure (ALF) is classically defined by coagulopathy and hepatic encephalopathy (HE); however, acute liver injury (ALI), i.e., severe acute hepatocyte necrosis without HE, has not been carefully defined nor studied. Our aim is to describe the clinical course of specifically defined ALI, including the risk and clinical predictors of poor outcomes, namely progression to ALF, the need for liver transplantation (LT) and death. METHODS: 386 subjects prospectively enrolled in the Acute Liver Failure Study Group registry between 1 September 2008 through 25 October 2013, met criteria for ALI: International Normalized Ratio (INR)≥2.0 and alanine aminotransferase (ALT)≥10 × elevated (irrespective of bilirubin level) for acetaminophen (N-acetyl-p-aminophenol, APAP) ALI, or INR≥2.0, ALT≥10x elevated, and bilirubin≥3.0 mg/dl for non-APAPALI, both groups without any discernible HE. Subjects who progressed to poor outcomes (ALF, death, LT) were compared, by univariate analysis, with those who recovered. A model to predict poor outcome was developed using the random forest (RF) procedure. RESULTS: Progression to a poor outcome occurred in 90/386 (23%), primarily in non-APAP (71/179, 40%) vs. only 14/194 (7.2%) in APAPpatients comprising 52% of all cases (13 cases did not have an etiology assigned; 5 of whom had a poor outcome). Of 82 variables entered into the RF procedure: etiology, bilirubin, INR, APAP level and duration of jaundice were the most predictive of progression to ALF, LT, or death. CONCLUSIONS: A majority of ALI cases are due to APAP, 93% of whom will improve rapidly and fully recover, while non-APAPpatients have a far greater risk of poor outcome and should be targeted for early referral to a liver transplant center.
Authors: Kama A Wlodzimirow; Saeid Eslami; Ameen Abu-Hanna; Martin Nieuwoudt; Robert A F M Chamuleau Journal: Hepatology Date: 2012-04 Impact factor: 17.425
Authors: Robert J Fontana; Paul H Hayashi; Jiezhun Gu; K Rajender Reddy; Huiman Barnhart; Paul B Watkins; Jose Serrano; William M Lee; Naga Chalasani; Andrew Stolz; Timothy Davern; Jayant A Talwakar Journal: Gastroenterology Date: 2014-03-27 Impact factor: 22.682
Authors: D Richard Cutler; Thomas C Edwards; Karen H Beard; Adele Cutler; Kyle T Hess; Jacob Gibson; Joshua J Lawler Journal: Ecology Date: 2007-11 Impact factor: 5.499
Authors: Sujith V W Weerasinghe; David S Moons; Peter J Altshuler; Yatrik M Shah; M Bishr Omary Journal: Hepatology Date: 2011-04 Impact factor: 17.425
Authors: R Todd Stravitz; Ton Lisman; Velimir A Luketic; Richard K Sterling; Puneet Puri; Michael Fuchs; Ashraf Ibrahim; William M Lee; Arun J Sanyal Journal: J Hepatol Date: 2011-05-19 Impact factor: 25.083
Authors: Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei Journal: Hepatology Date: 2002-03 Impact factor: 17.425
Authors: Greg C G Hugenholtz; Jelle Adelmeijer; Joost C M Meijers; Robert J Porte; R Todd Stravitz; Ton Lisman Journal: Hepatology Date: 2013-07-01 Impact factor: 17.425
Authors: Daniel R Ganger; Jody Rule; Jorge Rakela; Nathan Bass; A Reuben; R T Stravitz; Norman Sussman; Anne M Larson; Laura James; Charles Chiu; William M Lee Journal: Am J Gastroenterol Date: 2018-06-27 Impact factor: 12.045
Authors: Fien A von Meijenfeldt; R Todd Stravitz; Jingwen Zhang; Jelle Adelmeijer; Yoh Zen; Valerie Durkalski; William M Lee; Ton Lisman Journal: Hepatology Date: 2021-12-12 Impact factor: 17.298
Authors: Ellen G Driever; R Todd Stravitz; Jingwen Zhang; Jelle Adelmeijer; Valerie Durkalski; William M Lee; Ton Lisman Journal: Hepatology Date: 2021-05 Impact factor: 17.425